Literature DB >> 31403247

Neutrophil Extracellular Traps in Tissue and Periphery in Juvenile Dermatomyositis.

Bhargavi Duvvuri1, Lauren M Pachman2, Gabrielle Morgan2, Amer M Khojah2, Marisa Klein-Gitelman3, Megan L Curran4, Stephen Doty5, Christian Lood1.   

Abstract

OBJECTIVE: Neutrophils are key immune cells participating in host defense through several mechanisms, including the formation of neutrophil extracellular traps (NETs). This study was undertaken to investigate the role of neutrophils in juvenile dermatomyositis (JDM).
METHODS: Electron microscopy was used to identify neutrophils in tissue. NETs were also imaged using fluorescence microscopy and quantified using a myeloperoxidase-DNA enzyme-linked immunosorbent assay (ELISA) in plasma obtained from healthy children (n = 20), disease controls (n = 29), JDM patients (n = 66), and JDM patients with history of calcifications (n = 20). Clinical data included disease activity scores and complement C4 levels. Levels of immune complexes (ICs) and calprotectin were analyzed using ELISA.
RESULTS: Using electron microscopy, neutrophils were found to infiltrate affected muscle tissue, engulfing deposited calcium crystals. Uptake of the crystals led to neutrophil activation (P < 0.01) and subsequent phosphatidylinositol 3-kinase- and NADPH oxidase-dependent but peptidylarginine deiminase 4-independent formation of NETs, which contained mitochondrial DNA (P < 0.05), as confirmed in vivo (P < 0.001) and in vitro (P < 0.01). Peripheral NET levels were associated with calcinosis (P = 0.01), ICs (P = 0.008), and interleukin-8 levels (P = 0.004). Children with JDM had impaired NET clearance (P = 0.01), associated with autoantibody profiles including melanoma differentiation-associated protein 5 (P = 0.005), and depressed complement C4 levels (r = -0.72, P = 0.002). Furthermore, children with JDM showed evidence of neutrophil activation, with elevated levels of peroxidase activity (P = 0.02) and calprotectin (P < 0.01), which were associated with disease activity (P = 0.007), and dyslipidemia (odds ratio 4.7, P < 0.05).
CONCLUSION: We found novel mechanisms of both calcium crystal-mediated neutrophil activation and cell death in JDM pathophysiology. Targeting this pathway may reduce the frequency and extent of calcinosis, as well as prevent long-term development of comorbidities, including atherosclerosis.
© 2019, American College of Rheumatology.

Entities:  

Mesh:

Year:  2020        PMID: 31403247     DOI: 10.1002/art.41078

Source DB:  PubMed          Journal:  Arthritis Rheumatol        ISSN: 2326-5191            Impact factor:   10.995


  15 in total

Review 1.  NETosis in Rheumatic Diseases.

Authors:  Mehul P Jariwala; Ronald M Laxer
Journal:  Curr Rheumatol Rep       Date:  2021-01-28       Impact factor: 4.592

2.  Neutrophil activation in patients with anti-neutrophil cytoplasmic autoantibody-associated vasculitis and large-vessel vasculitis.

Authors:  Despina Michailidou; Bhargavi Duvvuri; Runa Kuley; David Cuthbertson; Peter C Grayson; Nader A Khalidi; Curry L Koening; Carol A Langford; Carol A McAlear; Larry W Moreland; Christian Pagnoux; Philip Seo; Ulrich Specks; Antoine G Sreih; Kenneth J Warrington; Tomas Mustelin; Paul A Monach; Peter A Merkel; Christian Lood
Journal:  Arthritis Res Ther       Date:  2022-06-29       Impact factor: 5.606

3.  Serum protein biomarkers for juvenile dermatomyositis: a pilot study.

Authors:  Shefa M Tawalbeh; Wilfredo Marin; Gabrielle A Morgan; Utkarsh J Dang; Yetrib Hathout; Lauren M Pachman
Journal:  BMC Rheumatol       Date:  2020-10-01

4.  Neutrophil dysregulation is pathogenic in idiopathic inflammatory myopathies.

Authors:  Nickie Seto; Jose Jiram Torres-Ruiz; Carmelo Carmona-Rivera; Iago Pinal-Fernandez; Katherine Pak; Monica M Purmalek; Yuji Hosono; Catia Fernandes-Cerqueira; Prateek Gowda; Nathan Arnett; Alexander Gorbach; Olivier Benveniste; Diana Gómez-Martín; Albert Selva-O'Callaghan; José C Milisenda; Josep M Grau-Junyent; Lisa Christopher-Stine; Frederick W Miller; Ingrid E Lundberg; J Michelle Kahlenberg; Adam I Schiffenbauer; Andrew Mammen; Lisa G Rider; Mariana J Kaplan
Journal:  JCI Insight       Date:  2020-02-13

Review 5.  Calcinosis Biomarkers in Adult and Juvenile Dermatomyositis.

Authors:  Melody P Chung; Carrie Richardson; David Kirakossian; Amir B Orandi; Lesley A Saketkoo; Lisa G Rider; Adam Schiffenbauer; Carlos A von Mühlen; Lorinda Chung
Journal:  Autoimmun Rev       Date:  2020-03-28       Impact factor: 9.754

6.  Mitochondrial Calcification.

Authors:  Bhargavi Duvvuri; Christian Lood
Journal:  Immunometabolism       Date:  2021-01-29

7.  A network-informed analysis of SARS-CoV-2 and hemophagocytic lymphohistiocytosis genes' interactions points to Neutrophil extracellular traps as mediators of thrombosis in COVID-19.

Authors:  Jun Ding; David Earl Hostallero; Mohamed Reda El Khili; Gregory Joseph Fonseca; Simon Milette; Nuzha Noorah; Myriam Guay-Belzile; Jonathan Spicer; Noriko Daneshtalab; Martin Sirois; Karine Tremblay; Amin Emad; Simon Rousseau
Journal:  PLoS Comput Biol       Date:  2021-03-08       Impact factor: 4.475

Review 8.  Role of Neutrophils in Systemic Vasculitides.

Authors:  Despina Michailidou; Tomas Mustelin; Christian Lood
Journal:  Front Immunol       Date:  2020-12-17       Impact factor: 7.561

9.  Autoantibodies Against Unmodified and Citrullinated Human Endogenous Retrovirus K Envelope Protein in Patients With Rheumatoid Arthritis.

Authors:  Xiaoxing Wang; Amanda Hefton; Kathryn Ni; Kennedy C Ukadike; Michael A Bowen; Mary Eckert; Anne Stevens; Christian Lood; Tomas Mustelin
Journal:  J Rheumatol       Date:  2021-08-01       Impact factor: 4.666

10.  IgG and IgA autoantibodies against L1 ORF1p expressed in granulocytes correlate with granulocyte consumption and disease activity in pediatric systemic lupus erythematosus.

Authors:  Christian Lood; Tomas Mustelin; Kennedy C Ukadike; Kathryn Ni; Xiaoxing Wang; Martin S Taylor; John LaCava; Lauren M Pachman; Mary Eckert; Anne Stevens
Journal:  Arthritis Res Ther       Date:  2021-05-29       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.